1,3-dicyclopropyl-3-hydroxyprop-2-en-1-one, 98%, 1g

(S)-1-(Pyridin-2-yl)ethanol, 95.0%, 5g

(4S,4'S)-2,2'-(2,3-Dihydro-1H-indene-2,2-diyl)bis(4-isopropyl-4,5-dihydrooxazole), 97%, 250mg

1-(5-(BENZYLOXY)PYRIDIN-2-YL)CYCLOPROPANECARBOXYLIC ACID, 95.0%, 250mg

4-Bromo-2-methyl-6-nitrophenol, 95.0%, 5g

Colonne en polypropylène SPE CHROMABOND® Drug II, 3 ml, 200 mg, 50 pièce(s)

4,5,9,10-Tetrabromoisochromeno[6,5,4-def]isochromene-1,3,6,8-tetraone, 95%, 1g

2-hydrazino-5,6-dimethoxy-1,3-benzothiazole, 95.0%, 250mg

3,4-Dichloro-5-(chlorosulfonyl)benzoic acid, 95+%, 1g

3-Methoxy-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzonitrile, 96%, 5g

(4-((4-Methylpiperidin-1-yl)sulfonyl)phenyl)boronic acid, 98%, 1g

5,7-Dichloro-3-isopropyl-3H-imidazo[4,5-b]pyridine, 95%, 50mg

(R)-alpha-Lipoic Acid>98.0%(HPLC)(T)5g